ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 85.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 94,938 shares of the biotechnology company's stock after purchasing an additional 43,836 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in ADMA Biologics were worth $1,898,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ADMA. Aigen Investment Management LP purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $583,000. Entropy Technologies LP purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $757,000. Lisanti Capital Growth LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $4,698,000. Chartwell Investment Partners LLC increased its holdings in shares of ADMA Biologics by 0.8% in the 3rd quarter. Chartwell Investment Partners LLC now owns 249,779 shares of the biotechnology company's stock valued at $4,993,000 after acquiring an additional 2,038 shares during the period. Finally, Los Angeles Capital Management LLC increased its holdings in shares of ADMA Biologics by 83.9% in the 3rd quarter. Los Angeles Capital Management LLC now owns 148,490 shares of the biotechnology company's stock valued at $2,968,000 after acquiring an additional 67,740 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ADMA. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright boosted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

Insider Buying and Selling

In other news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 10.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Young Kwon sold 60,000 shares of the firm's stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The trade was a 19.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock worth $8,224,121 in the last three months. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded up $0.18 during trading on Monday, hitting $19.22. 1,414,721 shares of the company were exchanged, compared to its average volume of 3,656,950. The company has a market cap of $4.54 billion, a price-to-earnings ratio of 68.18 and a beta of 0.64. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The firm's fifty day moving average price is $18.54 and its 200 day moving average price is $14.45. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period in the previous year, the firm earned $0.01 EPS. On average, sell-side analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.